Biosensors Of Singapore Eyes Bigger Share In China, Japan Stent Sales
This article was originally published in PharmAsia News
Executive Summary
Singapore's Biosensors plans to beef up its sales effort for drug-eluting stents in China in the wake of Johnson & Johnson's announced departure from that sector of the device industry. Biosensors also expects to increase its earnings from Japan through a licensing agreement with Terumo. With the exit of J&J from the stent market, Biosensors expects to increase its nearly 30% share of the $1 billion Chinese market. The Singapore firm's tie with Terumo is expected to provide a 20% share of the Japan market estimated to be worth as much as $600 million. (Click here for more